Navigation Links
Michael Langley, DVM, MBA, RAC Joins the Anson Group as a Regulatory Consultant
Date:1/30/2010

The Anson Group is pleased to announce that Dr. Michael Langley is joining the company as a regulatory consultant after retiring from Eli Lilly & Co. Dr. Langley served many roles during his career with Lilly in both animal science and human pharmaceutical products, including director of regulatory affairs and clinical research. Dr. Langley led a number of successful regulatory engagements including both European and US regulatory submissions.

Indianapolis, IN (Vocus) January 30, 2010 -- The Anson Group announces today the addition of Dr. Michael Langley to its regulatory consulting practice. Dr. Langley is joining Anson Group after his recent retirement from Eli Lilly and Co. He has worked in the pharmaceutical industry since 1983, and has had a range of responsibilities and a broad variety of pharmaceutical products.

Early in his career, Dr. Langley worked for Elanco Animal Health, a Division of Eli Lilly, in a number of roles with increasing responsibilities including market research manager, project manager of animal health research, Director of European Regulatory and Clinical Affairs, and finally director of clinical research.

In 2002, Dr. Langley transitioned from animal health products to human pharmaceuticals at Eli Lilly. His experience includes establishing research priorities and timelines, successfully leading teams through US and EU marketing applications.

As the Director for Regulatory Affairs for Eli Lilly, Dr. Langley led project teams in label negotiations with the FDA, and several sNDA and sBLAapplications which resulted in approvals. Additionally, he has successfully guided several IND submissions, and also worked with FDA officials to remove a clinical hold placed on one molecule.    

“As we further expand the depth and breadth of our regulatory team, the addition of Dr. Langley’s oncology and CVM experience significantly contributes to our goal of providing the most experienced personnel needed to meet the exacting demands of every client project.” states Colleen Hittle, RAC, Managing Partner.


About Anson Group
Headquartered in Carmel Indiana, Anson Group is a minority-owned independent consulting organization with over 14 years experience as a leading provider of services and strategies for FDA product approval and compliance for devices, drugs, biologics, and combination products. Anson Group’s team of experienced industry experts tailors both enterprise strategies and clearly-defined action plans that help its clients address crucial issues throughout the product life cycle. Anson works with clients in the United States, Europe, and Asia, from global pharmaceutical manufacturers to small pre-IPO or VC biotechnology and medical device start-ups.

###

Read the full story at http://www.prweb.com/releases/regulatory/01/prweb3540554.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Michael Troullis Appointed Chief Financial Officer of Quintiles Transnational Corp.
2. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
3. Genstar Names Michael Hurt to Its Strategic Advisory Board
4. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
5. MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Companys Scientific Advisory Board
6. Pharmasset Appoints Michael Rogers as Chief Development Officer
7. The Michael J. Fox Foundation Awards $2 Million to Shed Light on Role of LRRK2 and Alpha-Synuclein Genes in Parkinsons Disease
8. ImmunoVaccine Technologies appoints the Honourable Michael Kirby as Chair
9. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
10. Dr Michael Rosenblatt Appointed Non-Executive Director at Shire
11. Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Michael Langley, DVM, MBA, RAC Joins the Anson Group as a Regulatory Consultant
(Date:5/2/2016)... Willoughby, Ohio (PRWEB) , ... May 02, 2016 ... ... website. Designed with its clients in mind, the fresh look and added functionality ... capabilities. , “Recent years have seen a dynamic shift in agriculture – from ...
(Date:4/29/2016)... ... April 30, 2016 , ... The MIT bioLogic design ... the bioLogic team explored how bacterial properties can be applied to fabric and formed ... bacteria, which move in response to humidity change. The team harvested Natto cells and ...
(Date:4/29/2016)... April 29, 2016 According ... Market Research "Separation Systems for Commercial Biotechnology Market ... and Forecast 2015 - 2023", the separation systems ... 10,665.5 Mn in 2014 and is projected to ... to 2023 to reach US$ 19,227.8 Mn in ...
(Date:4/29/2016)... ... April 29, 2016 , ... Intelligent Implant Systems announced today that the ... for sale in the United States. These components expand the capabilities of the ... one-level sales beginning in October of 2015, the company has seen significant sales growth ...
Breaking Biology Technology:
(Date:4/13/2016)...  IMPOWER physicians supporting Medicaid patients in ... standard in telehealth thanks to a new partnership with ... IMPOWER patients can routinely track key health measurements, such ... and, when they opt in, share them with IMPOWER ... local retail location at no cost. By leveraging this ...
(Date:3/22/2016)... 22, 2016 According ... Market for Consumer Industry by Type (Image, Motion, ... (Communication & IT, Entertainment, Home Appliances, & ... to 2022", published by MarketsandMarkets, the market ... reach USD 26.76 Billion by 2022, at ...
(Date:3/15/2016)... , March 15, 2016 ... report published by Transparency Market Research "Digital Door Lock Systems ... Forecast 2015 - 2023," the global digital door lock systems ... Mn in 2014 and is forecast to grow at a ... of micro, small and medium enterprises (MSMEs) across the world ...
Breaking Biology News(10 mins):